Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis
Begüm Kocatürk, … , Magali Noval Rivas, Moshe Arditi
Begüm Kocatürk, … , Magali Noval Rivas, Moshe Arditi
Published June 6, 2023
Citation Information: JCI Insight. 2023;8(14):e169855. https://doi.org/10.1172/jci.insight.169855.
View: Text | PDF | Corrigendum
Research Article Inflammation Vascular biology

Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis

  • Text
  • PDF
Abstract

Kawasaki disease (KD) is the leading cause of acquired heart disease among children. Increased platelet counts and activation are observed during the course of KD, and elevated platelet counts are associated with higher risks of developing intravenous immunoglobulin resistance and coronary artery aneurysms. However, the role of platelets in KD pathogenesis remains unclear. Here, we analyzed transcriptomics data generated from the whole blood of patients with KD and discovered changes in the expression of platelet-related genes during acute KD. In the Lactobacillus casei cell wall extract (LCWE) murine model of KD vasculitis, LCWE injection increased platelet counts and the formation of monocyte-platelet aggregates (MPAs), upregulated the concentration of soluble P-selectin, and increased circulating thrombopoietin and interleukin 6 (IL-6). Furthermore, platelet counts correlated with the severity of cardiovascular inflammation. Genetic depletion of platelets (Mpl–/– mice) or treatment with an anti-CD42b antibody significantly reduced LCWE-induced cardiovascular lesions. Furthermore, in the mouse model, platelets promoted vascular inflammation via the formation of MPAs, which likely amplified IL-1B production. Altogether, our results indicate that platelet activation exacerbates the development of cardiovascular lesions in a murine model of KD vasculitis. These findings enhance our understanding of KD vasculitis pathogenesis and highlight MPAs, which are known to enhance IL-1B production, as a potential therapeutic target for this disorder.

Authors

Begüm Kocatürk, Youngho Lee, Nobuyuki Nosaka, Masanori Abe, Daisy Martinon, Malcolm E. Lane, Debbie Moreira, Shuang Chen, Michael C. Fishbein, Rebecca A. Porritt, Bernardo S. Franklin, Magali Noval Rivas, Moshe Arditi

×

Figure 3

Platelet depletion attenuates the severity of LCWE-induced KD vasculitis.

Options: View larger image (or click on image) Download as PowerPoint
Platelet depletion attenuates the severity of LCWE-induced KD vasculitis...
(A and B) Representative H&E-stained heart tissue sections (A) and heart vessel inflammation score (B) from LCWE-injected mice, or LCWE-injected mice that received either the platelet-depleting anti-CD42b antibody or IgG control at 1 week after LCWE injection (n = 7 to 8 mice/group). Scale bars: 200 μm. (C–E) Representative pictures of the abdominal aorta area (C), maximal abdominal aorta diameter (D), and abdominal aorta area measurements (E) from LCWE-injected mice, or LCWE-injected mice that received either the platelet-depleting anti-CD42b or IgG control at 1 week after LCWE injection (n = 7 to 8 mice/group). (F) Levels of IL-1B in the serum of PBS- or LCWE-injected mice that received either IgG isotype control or the platelet-depleting anti-CD42b antibody on day 1 or day 7 after LCWE injection (n = 4 to 7 mice/group). (G) Representative H&E staining and immunostaining staining of CD41 (red) in serial heart sections of WT mice injected with PBS, LCWE, or LCWE-injected mice treated with the platelet-depleting anti-CD42b. (H) CD41+ cell counts in the coronary artery of WT mice injected with PBS, LCWE, or LCWE-injected mice treated with the platelet-depleting anti-CD42b. Scale bars: 200 μm (H&E) and 100 μm (immunofluorescence). Each symbol represents 1 mouse. Results presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 obtained by 1-way ANOVA with Tukey’s multiple-comparison test (B and D–G).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts